标题/作者	年份
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ... New England Journal of Medicine 379 (22), 2108-2121	2018
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up J Haanen, F Carbonnel, C Robert, KM Kerr, S Peters, J Larkin, K Jordan Annals of oncology 28, iv119-iv142	2017
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, ... The Lancet Oncology 21 (1), 44-59	2020
A review of cancer immunotherapy toxicity LB Kennedy, AKS Salama CA: a cancer journal for clinicians 70 (2), 86-104	2020
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations G Curigliano, D Lenihan, M Fradley, S Ganatra, A Barac, A Blaes, ... Annals of Oncology 31 (2), 171-190	2020
Immune-related adverse events of checkpoint inhibitors M Ramos-Casals, JR Brahmer, MK Callahan, A Flores-Chávez, N Keegan, ... Nature reviews Disease primers 6 (1), 38	2020
A review of cancer immunotherapy: from the past, to the present, to the future K Esfahani, L Roudaia, NA Buhlaiga, SV Del Rincon, N Papneja, ... Current Oncology 27 (s2), 87-97	2020
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis Y Wang, S Zhou, F Yang, X Qi, X Wang, X Guan, C Shen, N Duma, ... JAMA oncology 5 (7), 1008-1019	2019
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial E Felip, N Altorki, C Zhou, T Csőszi, I Vynnychenko, O Goloborodko, ... The Lancet 398 (10308), 1344-1357	2021
Current state of melanoma diagnosis and treatment LE Davis, SC Shalin, AJ Tackett Cancer biology & therapy 20 (11), 1366-1379	2019
Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 17 (3), 255-289	2019
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) AR Lyon, T López-Fernández, LS Couch, R Asteggiano, MC Aznar, ... European heart journal 43 (41), 4229-4361	2022
Immunotherapies for hepatocellular carcinoma JM Llovet, F Castet, M Heikenwalder, MK Maini, V Mazzaferro, DJ Pinato, ... Nature reviews Clinical oncology 19 (3), 151-172	2022
Endocrine toxicity of cancer immunotherapy targeting immune checkpoints LS Chang, R Barroso-Sousa, SM Tolaney, FS Hodi, UB Kaiser, L Min Endocrine reviews 40 (1), 17-65	2019
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition) J Zhou, H Sun, Z Wang, W Cong, J Wang, M Zeng, W Zhou, P Bie, L Liu, ... Liver cancer 9 (6), 682-720	2020
Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association RD Kociol, LT Cooper, JC Fang, JJ Moslehi, PS Pang, MA Sabe, RV Shah, ... Circulation 141 (6), e69-e92	2020
Immune checkpoint inhibitors in melanoma MS Carlino, J Larkin, GV Long The Lancet 398 (10304), 1002-1014	2021
Cardiovascular toxicities associated with immune checkpoint inhibitors JR Hu, R Florido, EJ Lipson, J Naidoo, R Ardehali, CG Tocchetti, AR Lyon, ... Cardiovascular research 115 (5), 854-868	2019
Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ... Journal of Thoracic Oncology 13 (12), 1930-1939	2018
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma AL Cheng, C Hsu, SL Chan, SP Choo, M Kudo Journal of hepatology 72 (2), 307-319	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。